Wellington Management Group LLP Purchases 6,175,835 Shares of Haleon plc (NYSE:HLN)

Wellington Management Group LLP grew its stake in shares of Haleon plc (NYSE:HLN - Free Report) by 67.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,328,325 shares of the company's stock after buying an additional 6,175,835 shares during the period. Wellington Management Group LLP owned 0.34% of Haleon worth $146,232,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of HLN. Raymond James Financial Inc. purchased a new stake in shares of Haleon in the fourth quarter worth $42,193,000. Bank Julius Baer & Co. Ltd Zurich bought a new position in Haleon in the 4th quarter worth about $39,628,000. JPMorgan Chase & Co. boosted its position in shares of Haleon by 25.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 5,084,202 shares of the company's stock valued at $53,791,000 after acquiring an additional 1,026,939 shares during the last quarter. Arrowstreet Capital Limited Partnership bought a new stake in shares of Haleon during the 4th quarter valued at about $8,922,000. Finally, Bank of New York Mellon Corp grew its holdings in shares of Haleon by 29.8% during the fourth quarter. Bank of New York Mellon Corp now owns 2,071,017 shares of the company's stock worth $19,758,000 after purchasing an additional 475,934 shares in the last quarter. 6.67% of the stock is owned by hedge funds and other institutional investors.

Haleon Trading Up 2.8 %

NYSE:HLN traded up $0.26 during trading hours on Tuesday, reaching $9.53. The company's stock had a trading volume of 9,216,274 shares, compared to its average volume of 10,584,606. The firm has a 50-day simple moving average of $10.03 and a 200-day simple moving average of $9.85. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. Haleon plc has a 1 year low of $7.99 and a 1 year high of $10.80. The firm has a market capitalization of $43.03 billion, a price-to-earnings ratio of 28.02, a PEG ratio of 2.82 and a beta of 0.24.

Haleon (NYSE:HLN - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported $0.05 earnings per share for the quarter. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The company had revenue of $3.54 billion during the quarter, compared to analyst estimates of $3.38 billion. Research analysts expect that Haleon plc will post 0.43 EPS for the current fiscal year.

Haleon Increases Dividend

The company also recently announced a -- dividend, which will be paid on Thursday, June 5th. Stockholders of record on Friday, April 25th will be issued a $0.1166 dividend. This is a boost from Haleon's previous -- dividend of $0.05. The ex-dividend date is Friday, April 25th. This represents a dividend yield of 1.6%. Haleon's dividend payout ratio (DPR) is currently 58.97%.

Analyst Upgrades and Downgrades

HLN has been the topic of a number of recent analyst reports. Hsbc Global Res downgraded shares of Haleon from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Haleon in a research report on Monday, March 3rd. Sanford C. Bernstein lowered shares of Haleon from an "outperform" rating to a "market perform" rating in a research report on Wednesday, January 8th. Morgan Stanley downgraded Haleon from an "overweight" rating to an "equal weight" rating in a research report on Friday, January 10th. Finally, HSBC reiterated a "hold" rating on shares of Haleon in a report on Wednesday, March 5th. Six equities research analysts have rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $10.95.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.